SynthesisFrontiers in neuroscience2026
Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson's disease: a bibliometric analysis.
Synthesis in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PD is still managed symptomatically with levodopa, and no disease-modifying therapy is available, making effective treatment difficult. In recent years, preclinical and some clinical evidence have shown that glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists, GLP-1 RAs) can cross to varying degrees the blood-brain barrier and exert neuroprotective effects, including anti-inflammatory, antioxidant, and insulin-sensitizing actions. They also reduce pathological protein aggregation, regulate mitochondrial function, and enhance autophagy, demonstrating their therapeutic potential for PD. Therefore, systematically reviewing the research status, hotspots, and trends of GLP-1 receptor agonists in PD is crucial for understanding the dynamic development of this field. Methods: Systematic searches were performed in the Web of Science Core Collection and Scopus databases to identify literature on GLP-1 receptor agonists and PD. Bibliometric analyses were conducted using CiteSpace and VOSviewer to evaluate publication trends, collaborative networks, co-citation patterns, and research hotspots. The search period spanned from database inception to April 14, 2026. Results: A total of 282 articles from WoS and Scopus were included for bibliometric analysis. The top three countries are China, the United States, and the United Kingdom. Major institutions include University College London, Shanxi Medical University, Henan University of Chinese Medicine, and Lancaster University, with authors Hölscher, Athauda, Aviles-Olmos, and Li. Hotspots focus on oxidative stress, insulin resistance, alpha-synuclein, blood-brain barrier, and exendin-4. Emerging themes with increasing research attention include mild cognitive impairment, GIP/GLP-1 dual agonists, and blood-brain barrier. Conclusion: PD is a multifactorial neurodegenerative disorder characterized by complex and heterogeneous pathological mechanisms, supporting the exploration of multi-target therapeutic strategies. GLP-1 receptor signaling is widely distributed in the central nervous system and peripheral metabolic tissues, suggesting a potential link between metabolic regulation and neurodegenerative processes. Bibliometric analysis indicates that GLP-1 receptor agonists have attracted increasing research attention in PD, particularly in relation to metabolic dysfunction, neuroinflammation, and mitochondrial pathways. However, current clinical evidence remains inconsistent, with findings influenced by drug heterogeneity, study populations, and methodological differences. Overall, GLP-1 receptor-related mechanisms represent an emerging and evolving research direction in PD, warranting further experimental and clinical investigation. Systematic review registration: https://osf.io/u7wdy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.